Drug pricing will come under more government scrutiny.
"U.S. Investigative Panel to look into Drug Pricing next year"
By Sarah N. Lynch
U.S. congressman seeks interviews with Valeant employees tied to Philidor Reuters
Democrats call for subpoena of Valeant's Pearson and Turing's Shkreli MarketWatch
Valeant played a key role in building, operating Philidor RX Reuters
Valeant Dumps Philidor As Stock Keeps Hemorrhaging Investor's Business Daily
Valeant cuts ties with “phantom" pharmacy Philidor USA TODAY
I HATE Annuities…and So Should You! Fisher Investments Sponsored
WASHINGTON (Reuters) - A U.S. House of Representatives investigative panel said it plans to hold a 2016 hearing on skyrocketing drug costs, a move that comes at a time when Valeant Pharmaceuticals International is facing increased scrutiny into its pricing practices.
A spokeswoman for the U.S. House Committee on Oversight & Government Reform said on Monday the panel is conducting a thorough investigation into drug pricing and has reached out to drug companies to gather information.
Earlier this month, the U.S. Senate Special Committee on Aging launched a new probe into drug pricing at Valeant (VRX.TO) (VRX.N) and Turing, signaling growing bipartisan agreement on the need to review the rising cost of prescription drugs in the United States.